Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07577427
Starting soon Observational

Benign and Malignant Adrenal Gland Surgery: Single Center Experience

NCT07577427 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Roma La Sapienza
Phase
Observational
Started
2026-05-03
Last updated
2026-05-11

Condition(s) studied

Adrenal Gland Disease

Investigational drug(s) / intervention(s)

Surgery with and without the aid of Indocyanine Green (ICG)

Surgery with and without the aid of Indocyanine Green (ICG): NO DIFFERENCES

Study summary

PATIENTS AFFECTED BY ADRENAL GLAND DISEASE WITH SURGICAL INDICATION OF ROBOTIC OR LAPAROSCOPIC ADRENALECTOMY

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ADRENAL GLAND DISEASE Exclusion Criteria: \-

Primary outcome measure(s)

  • POSTOPERATIVE COMPLICATIONS — FROM ENROLLMENT TO THE END OF TREATMENT AT 5 YEARS
    CLAVIEN-DINDO SCORE

Trial sites (1)

FacilityCityRegionStatus
Policlinico Umberto I Roma Italy

More University of Roma La Sapienza trials in Italy

Oral Health and Systemic Diseases: Survey of General Practitioners Recruiting
Use of 'Mechanical Power' as a Predictor of Increased Serum and Pulmonary Proinflammatory Cytokine Concentrations in Patients With Acute Hypoxemic Respiratory Failure: A Prospective Observational Study Recruiting
Pentabiocel in Pediatric IBS Starting soon
Post-Debonding Finishing in Orthodontics Recruiting
Pelvic Floor Ultrasound Before Induction of Labour and Labour Outcome Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07577427 on ClinicalTrials.gov ↗ ← All trials in Italy